Fecal Microbiota Transplantation for Decolonization of Carbapenem-resistant Enterobacteriaceae

Starting soon · Not applicable · Has a placebo group

Conditions studied: Carbapenem-Resistant Enterobacteriaceae Infection, Fecal Microbiota Transplantation

In brief

The emergence of multidrug-resistant organisms (MDROs) has become one of the major threats to the healthcare system in Hong Kong in recent years. The situation is particularly worrisome for carbapenem-resistant Enterobacteriaceae (CRE). Taking Queen Mary Hospital as an example, the number of CRE cases has surged from 24 in year 2014 to 625 in year 2021. The case burden in Hong Kong is therefore substantial when all 43 public hospitals and institutions in Hong Kong are considered. With the widespread use of broad-spectrum antibiotics and active case screening, the number of CRE cases is expected to further increase in an exponential manner. Given that colonization with MDROs is due to gut dysbiosis from antibiotic use, a normal intestinal microbiota is apparently crucial in protecting hosts from colonization with MDROs including CRE. Fecal microbiota transplantation (FMT), which involves the infusion of stool from a healthy donor to the gastrointestinal (GI) tract of a recipient, has gained popularity in recent years to restore colonic microbial diversity in various diseases associated with gut dysbiosis, e.g. Clostridium difficile (CD) infection, ulcerative colitis and even metabolic diseases. The investigators aim to conduct a double-blind randomized controlled trial to evaluate the benefit of FMT via upper GI delivery (oral capsules) on CRE clearance.

Key facts

Study ID

NCT05981430

Run by

The University of Hong Kong

People needed

80

Starts

2026-11-01

Expected to finish

2028-06-30

Last updated by the study team

2026-05-13

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All adult patients aged 18 or above admitted to the medical ward of Queen Mary Hospital, the teaching hospital of the University of Hong Kong
• Rectal swabs or stool specimens showing the presence of CRE
• Positive CRE specimen within one week of commencement

You may not qualify if…

• Pregnancy
• Severe immunodeficiency (e.g. advanced human immunodeficiency virus infection (CD4 lymphocyte count ≤200/mm3), myelosuppressive chemotherapy)
• Significant neutropenia (absolute neutrophil count ≤1.0 x 109/L)
• Recent antibiotic use within 30 days prior to consent
• Contraindications for capsule ingestion (dysphagia or gastrointestinal dysmotility).

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.